Alpha Tau Medical develops and commercializes Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a targeted treatment for solid tumors that utilizes interstitial alpha-emitting sources to deliver localized radiation while minimizing damage to surrounding healthy tissue. This technology addresses the challenge of effectively treating various cancers, including skin, prostate, and pancreatic cancers, by providing a highly potent and conformal radiation dose directly within the tumor.
Funding
$92M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are difficult to treat effectively with conventional radiation therapy due to the challenge of delivering a sufficient dose to the tumor while minimizing damage to surrounding healthy tissue. This limitation can result in incomplete tumor eradication and significant side effects for patients.
Solution
Alpha Tau Medical has developed Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a targeted cancer treatment that delivers localized alpha radiation directly to solid tumors. Alpha DaRT involves the interstitial placement of radioactive sources within the tumor, releasing high-energy alpha particles over a short range (several millimeters). This approach enables a highly potent and conformal radiation dose to be delivered focally within the tumor, sparing adjacent healthy tissue and reducing the risk of systemic side effects. The technology is being investigated for the treatment of various solid cancers.
Target Audience
The primary target audience includes oncologists, radiation oncologists, and hospitals specializing in the treatment of solid tumors, as well as patients with solid cancers who are seeking alternative or adjunctive treatment options.
Features
- Interstitial placement of Alpha DaRT sources directly into the tumor
- Emission of short-lived alpha particles with high linear energy transfer (LET)
- Localized radiation delivery with a range of several millimeters
- Targeted destruction of cancer cells while sparing surrounding healthy tissue
- Applicability to a range of solid tumor types, including skin, oral cavity, prostate, pancreatic, and breast cancers
- Ongoing clinical trials to evaluate safety and efficacy in various indications